Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc., a Delaware corporation, on April 14, 2025, covering events occurring on April 12, 2025. The Company is an emerging growth company with its principal executive offices in San Antonio, Texas. Its common stock and tradeable warrants trade on The Nasdaq Stock Market LLC under the symbols BIAF and BIAFW, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of a director from the Board of Directors. On April 12, 2025, Stuart Diamond notified the Company of his decision not to stand for re-election at the 2025 Annual Meeting of Stockholders. Mr. Diamond will continue to serve as a director until the conclusion of the 2025 Annual Meeting.
Management Commentary and Risks
Management explicitly stated that Mr. Diamond's decision not to seek re-election was not the result of any disagreement with the Company regarding its operations, policies, or practices. No other risks, contingencies, unusual items, or forward-looking guidance were disclosed in this filing.
Key Facts for Investor Verification
- Stuart Diamond will not be a candidate for re-election at the 2025 Annual Meeting.
- Mr. Diamond remains on the Board until the 2025 Annual Meeting concludes.
- The departure is not attributed to any disagreement with Company management or policy.
- No financial results or operational updates are included in this specific filing.